Steven Burrill Explains His Rosy 2005 Pharmacogenomics Outlook | GenomeWeb

At A Glance

Name: Steven Burrill

Title: CEO of Burrill & Company —1994 to present

Background: Technology and sciences consultant, Ernst & Young — 1966-1994

Steven Burrill, CEO and founder of the merchant bank Burrill & Company, has watched the ups and downs of the biotechnology industry for the past 35 years. A recent bank release, “Burrill’s Biotech Outlook 2005,” looks back on 2004 to assess last year’s predictions, and forward to an optimistic 2005 for pharmacogenomics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.